These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33721598)

  • 1. Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies.
    Davis CW; Kallweit U; Schwartz JC; Krahn LE; Vaughn B; Thorpy MJ
    Sleep Med; 2021 May; 81():210-217. PubMed ID: 33721598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials.
    Meskill GJ; Davis CW; Zarycranski D; Doliba M; Schwartz JC; Dayno JM
    CNS Drugs; 2022 Jan; 36(1):61-69. PubMed ID: 34935103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
    Szakacs Z; Dauvilliers Y; Mikhaylov V; Poverennova I; Krylov S; Jankovic S; Sonka K; Lehert P; Lecomte I; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials.
    Watson NF; Davis CW; Zarycranski D; Vaughn B; Dayno JM; Dauvilliers Y; Schwartz JC
    CNS Drugs; 2021 Dec; 35(12):1303-1315. PubMed ID: 34822113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
    Dauvilliers Y; Lecendreux M; Lammers GJ; Franco P; Poluektov M; Caussé C; Lecomte I; Lecomte JM; Lehert P; Schwartz JC; Plazzi G
    Lancet Neurol; 2023 Apr; 22(4):303-311. PubMed ID: 36931805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study.
    Dauvilliers Y; Arnulf I; Szakacs Z; Leu-Semenescu S; Lecomte I; Scart-Gres C; Lecomte JM; Schwartz JC;
    Sleep; 2019 Oct; 42(11):. PubMed ID: 31529094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
    Dauvilliers Y; Bassetti C; Lammers GJ; Arnulf I; Mayer G; Rodenbeck A; Lehert P; Ding CL; Lecomte JM; Schwartz JC;
    Lancet Neurol; 2013 Nov; 12(11):1068-75. PubMed ID: 24107292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pitolisant for treating patients with narcolepsy.
    Li S; Yang J
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):79-84. PubMed ID: 31937172
    [No Abstract]   [Full Text] [Related]  

  • 9. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial.
    Dauvilliers Y; Shapiro C; Mayer G; Lammers GJ; Emsellem H; Plazzi G; Chen D; Carter LP; Lee L; Black J; Thorpy MJ
    CNS Drugs; 2020 Jul; 34(7):773-784. PubMed ID: 32588401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
    Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
    Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review.
    Fabara SP; Ortiz JF; Anas Sohail A; Hidalgo J; Altamimi A; Tama B; Patel UK
    Cureus; 2021 Jul; 13(7):e16095. PubMed ID: 34345566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world treatment of pediatric narcolepsy with pitolisant: A retrospective, multicenter study.
    Triller A; Pizza F; Lecendreux M; Lieberich L; Rezaei R; Pech de Laclause A; Vandi S; Plazzi G; Kallweit U
    Sleep Med; 2023 Mar; 103():62-68. PubMed ID: 36758348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: A meta-analysis from randomized controlled trials.
    Wang J; Li X; Yang S; Wang T; Xu Z; Xu J; Gao H; Chen G
    Pharmacol Res; 2021 May; 167():105522. PubMed ID: 33667687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test.
    van der Heide A; van Schie MK; Lammers GJ; Dauvilliers Y; Arnulf I; Mayer G; Bassetti CL; Ding CL; Lehert P; van Dijk JG
    Sleep; 2015 Jul; 38(7):1051-8. PubMed ID: 25902810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pitolisant: A Review in Narcolepsy with or without Cataplexy.
    Lamb YN
    CNS Drugs; 2020 Feb; 34(2):207-218. PubMed ID: 31997137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy.
    Setnik B; McDonnell M; Mills C; Scart-Grès C; Robert P; Dayno JM; Schwartz JC
    Sleep; 2020 Apr; 43(4):. PubMed ID: 31626696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.
    Black J; Swick T; Bogan R; Lai C; Carter LP
    Sleep Med; 2016 Aug; 24():57-62. PubMed ID: 27810187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating pitolisant as a narcolepsy treatment option.
    de Biase S; Pellitteri G; Gigli GL; Valente M
    Expert Opin Pharmacother; 2021 Feb; 22(2):155-162. PubMed ID: 32941089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use.
    Kollb-Sielecka M; Demolis P; Emmerich J; Markey G; Salmonson T; Haas M
    Sleep Med; 2017 May; 33():125-129. PubMed ID: 28449891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
    Dauvilliers Y; Mignot E; Del Río Villegas R; Du Y; Hanson E; Inoue Y; Kadali H; Koundourakis E; Meyer S; Rogers R; Scammell TE; Sheikh SI; Swick T; Szakács Z; von Rosenstiel P; Wu J; Zeitz H; Murthy NV; Plazzi G; von Hehn C
    N Engl J Med; 2023 Jul; 389(4):309-321. PubMed ID: 37494485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.